FDA denies OTC monitoring request
This article was originally published in The Tan Sheet
Executive Summary
A request by the Synthetic Organic Chemical Manufacturers Association for FDA to implement a program for monitoring the impurity profiles of imported OTC drugs is denied. The agency's Oct. 13 1response to SOCMA's 2006 citizen 2petition says FDA's existing sampling and testing program for drug products and its good manufacturing practice inspection and surveillance efforts are "more comprehensive and appropriate" than SOCMA's recommendations (3"The Tan Sheet" Nov. 5, 2007). FDA denied most of SOCMA's other provisions, including requests to identify foreign facilities as a significant risk factor in inspections and risk-ranking foreign and domestic drug firms together. However, the agency did accede to the association's request for a publicly available database of foreign and domestic drug manufacturers, mainly because FDA is already developing such a system
You may also be interested in...
Import Contamination Risk Looms Larger For OTCs, Ex-Regulators Say
Over-the-counter drugs made with imported ingredients are at greater risk of contamination than prescription products, experts told a House panel on Nov. 1
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.